ESMO Handbook of Immuno-Oncology

2018 ESMO Handbook for Immuno-Oncology Cover

Download the complete book (PDF) (ESMO Members only)

Take the handbook CME test (ESMO Members only)

Watch the video presenting the Handbook by John B.A.G. Haanen , co-editor of the ESMO Handbook of Immuno-oncology.

Now available for e-readers!

ESMO members: You can now read this handbook on your iPad, tablet or Kindle! Download the .epub file for iPads and tablets or the .mobi file for Kindle. You will need to be logged in to your ESMO account to download the files.

.mobi .epub

Over the past decade, the field of immuno-oncology has truly come of age and is rapidly evolving. Within just a few years, immunotherapy has been approved as an important treatment option for patients across many cancer types.The ESMO Handbook of Immuno-Oncology was written by specialists in the field and covers many aspects of immuno-oncology, from basic immunology to the current state-of-the-art clinical immunotherapy in different disease types, including management of immune-related toxicities.This comprehensive overview provides a strong base to understand the theory, mechanisms of action, clinical developments and the future of immuno-oncology, and, therefore, is a “must read” for any professional involved in the care of cancer patients.

Section 1: Introduction to immunology and immunotherapy

1.1 Immune Checkpoints

1.2 Adoptive T Cell Therapy

1.3 Vaccines (Dendritic Cell Vaccines, Peptide Vaccines, DNA Vaccines, RNA Vaccines, Oncolytic Viruses)

1.4 Biomarkers for Immunotherapy

1.5 Resistance to Immunotherapy

Section 2: Immunotherapies in specific disease groups –  State of the art

2.1 Melanoma

2.2 Merkel Cell Carcinoma

2.3 Thoracic Malignancies

2.3.1 Non-small Cell Lung Cancer

2.3.2 Small Cell Lung Cancer

2.3.3 Mesothelioma

2.3.4 Other Thoracic Malignancies: Thymic Malignancies and Others

2.4 Genitourinary Malignancies

2.4.1 Renal Cancer

2.4.2 Bladder Cancer

2.5 Gastrointestinal Malignancies

2.5.1 Microsatellite Instability-high

2.5.2 Gastric and Oesophageal Malignancies

2.5.3. Hepatocellular Carcinoma

2.6 Immunotherapy in Head and Neck Tumours (HPV+ and HPV-)

2.7 Immunotherapies in Lymphoma

2.8 Gynaecological Malignancies

Section 3: Implications for clinical practice

3.1 Management of Adverse Events Related to Immune Checkpoint Blockade

3.2 Immune Checkpoint Blockade: Response Patterns and Assessment of Response

3.3 Immunotherapy in Special Populations

3.4 Cancer Immunotherapy Trials: Challenges and Opportunities

3.5 Future Perspectives